PCM
ARQT icon

Pinz Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Pinz Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,500
Closed -$130K – 407
2021
Q1 		$130K Buy
+4,500
New +$141K 0.03% 160

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Pinz Capital Management's ARQT Position: Q2 2021 in Review

Pinz Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2021, closing a stake of 4,500 shares — an estimated $130K sold.

Pinz Capital Management first reported a position in ARQT in Q1 2021 and held it in 1 quarter. The position peaked at $130K in Q1 2021. 102 funds tracked by Wall St. Rank hold ARQT as of Q2 2021.

  • Pinz Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Pinz Capital Management sold 4,500 Arcutis Biotherapeutics shares in Q2 2021, an estimated $130K.
  • Pinz Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 1 quarter.
  • Pinz Capital Management's Arcutis Biotherapeutics position peaked at $130K in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2021.

Based on Pinz Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.